Unusual volume stocks in Tuesday's session
By Mill Chart
Last update: Apr 16, 2024
Unusual volume stocks in Tuesday's session
Today's unusual volume stocks
| Ticker | Change | Comment |
|---|---|---|
| SNGX | 14.89% | Today, SOLIGENIX INC (NASDAQ:SNGX) stands out with a high volume of 7.77M shares. The share price of NASDAQ:SNGX increased by 14.89% today, reflecting positive market movement. In comparison to the average daily volume of the last 50 days, the current volume is 172.0% above. This suggests a notable change in trading activity. |
| INDO | -13.24% | The trading activity for INDONESIA ENERGY CORP LTD (NYSEARCA:INDO) has surged with a volume of 5.21M shares today. NYSEARCA:INDO is declining 13.24% today. This volume is 179.0% above the average 50 day volume. |
| PRFX | -18.37% | PAINREFORM LTD's (NASDAQ:PRFX) traded a high volume of 200.54K shares. This decline in share price leads to a decrease of 18.37%. The average volume measured over 50 days is 155.49K, so this is 28.97% above the average volume. |
| ONVO | -11.85% | ORGANOVO HOLDINGS INC (NASDAQ:ONVO) has an unusual volume of 1.5M shares. The share price decreased by 11.85%. Compared to the average daily volume of the past 50 days, the current volume is 26.07% above, suggesting an unusual level of trading activity. |
| OMQS | -24.29% | OMNIQ CORP (NASDAQ:OMQS) has an unusual volume of 585.41K shares. NASDAQ:OMQS is declining 24.29% today. The average volume over the last 50 days is 419.11K, making today's volume 39.68% above the average. This signifies a notable change in market participation. |
| CLDI | -58.47% | CALIDI BIOTHERAPEUTICS INC (NYSEARCA:CLDI) has an unusual volume of 3.77M shares. The share price decreased by 58.47%. This is 645.0% above the average daily volume of the last 50 days. A press release (Calidi Biotherapeutics, Inc. Announces Pricing of $6.1 Million Public Offering) was released earlier today. |
| RCON | -7.79% | 1.38M shares of RECON TECHNOLOGY LTD-CLASS A (NASDAQ:RCON) exchanged hands today. Shares are falling by 7.79%. This volume is 90.82% above the average 50 day volume. |
| PRZO | -20.42% | The trading volume of PARAZERO TECHNOLOGIES LTD (NASDAQ:PRZO) today is 12.14M shares, which is considered unusual. The share price decreased by 20.42%. The average volume over the last 50 days is 1.17M, making today's volume 936.0% above the average. This signifies a notable change in market participation. Earlier today the company had a press release: ParaZero Develops Counter Drone Solutions Leveraging Its Unique Technology. |
| HUSA | -12.04% | Today's trading session witnessed an unusual volume of 1.7M shares for HOUSTON AMERICAN ENERGY CORP (NYSEARCA:HUSA). The price decline of 12.04% reflects a downward movement in NYSEARCA:HUSA shares. This is 195.0% above the average daily volume of the last 50 days. |
| MRNS | -1.54% | Today's trading session witnessed an unusual volume of 12.41M shares for MARINUS PHARMACEUTICALS INC (NASDAQ:MRNS). The share price decreased by 1.54%. The average daily volume over the past 50 days is 1.17M. Hence, the current volume is 959.0% above the average volume, indicating a deviation from the usual trading pattern. Yesterday the company had a press release: Marinus Pharmaceuticals Provides Update on the Phase 3 RAISE Trial and Reports Preliminary First Quarter 2024 Financial Results. |
To see the full list of unusual volume stocks you can use our unusual volume stocks screener.
SOLIGENIX INC
NASDAQ:SNGX (5/17/2024, 8:28:34 PM)
After market: 0.385 -0.01 (-1.94%)0.3926
+0 (+0.67%)
SNGX News
3 days ago - Soligenix, Inc.Positive Clinical Results from HyBryte™ Compatibility Study in the Treatment of Cutaneous T-Cell Lymphoma Published in JEADV Clinical Practice/PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing...
6 days ago - BusinessInsiderSNGX Stock Earnings: Soligenix Beats EPS, Misses Revenue for Q1 2024InvestorPlace - Stock Market News, Stock Advice & Trading Tips Soligenix (NASDAQ:SNGX) just reported results for the first quarter of 2024.Sol...
6 days ago - InvestorPlaceSNGX Stock Earnings: Soligenix Beats EPS, Misses Revenue for Q1 2024SNGX stock results show that Soligenix beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
9 days ago - ChartmillWhich stocks are moving after the closing bell on Friday?What's going on in today's after hours session
9 days ago - Soligenix, Inc.Soligenix Announces Recent Accomplishments And First Quarter 2024 Financial Results/PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing...
13 days ago - Soligenix, Inc.Soligenix to Present at Upcoming Conferences/PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing...
24 days ago - Soligenix, Inc.Soligenix Extends Patent Protection for its Filovirus Vaccine Platform to the United Kingdom and South Africa/PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing...
a month ago - Soligenix, Inc.Soligenix Announces Pricing of $4.75 Million Public Offering/PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) ("Soligenix" or the "Company"), a late-stage biopharmaceutical company focused on developing and commercializing...
a month ago - InvestorPlaceToday’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on ThursdayPre-market stock movers are worth checking out as we dive into all of the biggest news sending shares higher and lower on Thursday morning!
On Monday, Soligenix Inc (NASDAQ:SNGX) received an FDA orphan drug designation for the active ingredient in MarVax, the subunit protein vaccine of recombinantly expressed Marburg marburgvirus (MARV) glycoprotein, for the prevention and post-exposure prophylaxis against MARV infection. In addition to providing a seven-year term of market exclusivity upon final FDA approval, orphan drug designation also positions Soligenix to be able to leverage a wide range of financial and regulatory benefits, i
a month ago - InvestorPlaceWhy Are Stocks Up Today?Stocks are up today and investors wondering what's behind that rally have come to the right place as we have the latest news for Monday!
